December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from BioInvent

< Previous 1 2 Next >
BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL
BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer... 
From PR Newswire
BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today... 
Tickers CASI
From PR Newswire
BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data
BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world's leading cancer... 
From PR Newswire
BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc.
BioInvent International AB (OMXS: BINV ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced... 
Tickers PFE
From PR Newswire
BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and... 
Tickers BOVNF
From PR Newswire
Nomination Committee appointed for BioInvent International's Annual General Meeting 2021
The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent) Annual General Meeting in 2021 have now been appointed. 
From PR Newswire
Record date for reverse share split in BioInvent International determined
At the Extraordinary General Meeting of BioInvent International AB (publ) ("BioInvent") on 27 November 2020, a reverse share split was resolved upon, whereby twenty-five existing shares will be... 
From PR Newswire
Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020
BioInvent International AB's (publ) ("BioInvent") (OMXS: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the Board of Directors' resolution on a directed issue of 29,395,311... 
From PR Newswire
BioInvent strengthens Investor Relations
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
Tickers BOVNF
From PR Newswire
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10
Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical development for... 
Tickers BOVNF
From PR Newswire
BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and... 
From PR Newswire
BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35th Anniversary Annual Meeting
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
From PR Newswire
BioInvent presents promising new clinical and preclinical data on anti-FcγRllB antibody, BI-1206, at the ASH Annual Meeting
- Signs of efficacy as first responses observed in lymphoma patients who have relapsed after treatment with rituximab 
From PR Newswire
BioInvent Interim Report January 1 - September 30, 2020
Tickers BOVNF CASI
From PR Newswire
Notice to Extraordinary General Meeting in BioInvent International AB
The Board of Directors in BioInvent International AB ("BioInvent" or the "Company") has resolved: 
Tickers BOVNF
From PR Newswire
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer... 
Tickers CASI
From PR Newswire
CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial
- BI-1808 is a novel mechanism of action antibody discovered through BioInvent's unique proprietary F.I.R.S.T™ technology platform 
From PR Newswire
BioInvent receives €2 million milestone from Daiichi Sankyo
Payment related to development of GARP directed antibody into Phase I clinical trial 
From PR Newswire
BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and... 
From PR Newswire
BioInvent to present data on BI-1808, an anti-TNFR2 antibody, at the SITC 35th Anniversary Annual Meeting
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
From PR Newswire
BioInvent Interim Report January 1 - June 30, 2020
Successful financing underpins exciting pipeline progress 
From PR Newswire
Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020
BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m.... 
Tickers BOVNF
From PR Newswire
BioInvent's BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in... 
Tickers BOVNF
From PR Newswire
BioInvent to Host Key Opinion Leader Call on Enhancing Checkpoint Inhibitors for the Treatment of Solid Cancers
Call & Webcast on Tuesday, July 21 at 10 a.m. Eastern Time 
From PR Newswire
BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.
BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license... 
Tickers BOVNF
From PR Newswire
BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
Tickers BOVNF
From PR Newswire
BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,... 
Tickers MRK
From PR Newswire
BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies
- Proof of concept for both agonistic and ligand-blocking TNFR2 targeting antibodies 
From PR Newswire
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
- Proof of concept for novel oncolytic virus with differentiated anti-CTLA4 antibody 
From PR Newswire
Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020
BioInvent International AB ("BioInvent") (OMXS: BINV) today announces, on behalf of the nomination committee and major shareholders, the proposal to elect Dr. Thomas Hecht as new Board member at the... 
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.